Certain geriatric factors can predict how patients with mCRC will tolerate chemotherapy

This article originally appeared here.
Share this content:
Geriatric Factors Can Foretell Tolerances to Chemotherapy
Geriatric Factors Can Foretell Tolerances to Chemotherapy

(HealthDay News) -- For elderly patients with metastatic colorectal cancer (mCRC), scores on the Mini-Mental State Examination (MMSE) and Instrumental Activities of Daily Living (IADL) were predictive of severe toxicity or unexpected hospitalization after fluorouracil-based chemotherapy with or without irinotecan (IRI), according to research published online March 4 in the Journal of Clinical Oncology.

Thomas Aparicio, M.D., Ph.D., of the University of Paris, and colleagues conducted a study involving 123 elderly patients ranging in age from 75 to 91 years with mCRC to determine what geriatric factors predict chemotherapy feasibility.

The researchers found that in elderly patients with mCRC, factors that were significant predictors for grade 3 to 4 toxicity due to chemotherapy included IRI arm, MMSE less than or equal to 27/30, and impaired IADL. For elderly patients receiving a 33 percent reduced dose of chemotherapy, the predictors were alkaline phosphates above two times the upper limit of normal and IRI arm. For unexpected hospitalization, MMSE less than or equal to 27/30 and Geriatric Depression Scale less than or equal to two were significant predictors.

"In conclusion, our study is the first to prospectively demonstrate that geriatric characteristics are independent predictive factors of tolerance to chemotherapy and toxicity in mCRC," the authors write. "Intensive chemotherapy should be used with caution in patients who have cognitive impairment or dependency. Larger studies are needed to confirm our results."

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs